معرفی
Amit Nathubhai is a Senior Lecturer in Pharmacology at the University of Northampton, Faculty of Arts, Science and Technology, where he leads the Pharmacology program and teaches core chemistry and pharmacology modules. He has previously held academic and research positions at the University of Sunderland and the University of Bath.
- PhD in Organic and Medicinal Chemistry – University of Bath (2010)
- MSc in Biological Chemistry – University of Leicester (2005)
- BSc in Biological Chemistry – University of Leicester (2004)
Amit's research lies at the intersection of chemistry and biology, focusing on the design and evaluation of small-molecule inhibitors targeting enzymes such as tankyrases and α-methylacyl-CoA racemase (AMACR). His work aims to develop molecular tools and potential therapeutics for diseases including colorectal and prostate cancer, idiopathic pulmonary fibrosis (IPF), type-2 diabetes, and fibrotic conditions. He employs structure-activity relationship (SAR) studies and structure-based design to optimize inhibitor potency and selectivity.
The most recent publications highlight a consistent focus on tankyrase inhibitors, particularly 2-arylquinazolin-4-ones and related heterocyclic scaffolds, with increasing emphasis on isoform selectivity and dual-site binding. His research also explores AMACR inhibition for prostate cancer and has contributed to the development of novel assays and prodrug systems. Collectively, his work demonstrates a strong trajectory in medicinal chemistry with applications in oncology and metabolic diseases.
Amit has secured multiple research grants and completed a company secondment fellowship at AstraZeneca (Mölndal) and the University of New York, supported by the MRC. While no formal advising relationships or student names are listed, his role as a senior lecturer and program leader suggests mentorship of undergraduate and postgraduate students.
He has been involved in collaborative research with institutions including the University of Dundee, University of Bath, University of New York, and AstraZeneca. His laboratory work focuses on synthetic organic chemistry, enzyme kinetics, and cellular evaluation of novel compounds. Future work is likely to expand on isoform-selective inhibitors and their application in regenerative medicine and metabolic disorders.
